A Therapeutically Targetable Mechanism of BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia

Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) poses a major problem for the treatment of chronic myeloid leukemia (CML). IM resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding. However, in many instances there is no mutation in BCR-ABL, and th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ma, Leyuan, Shan, Yi, Bai, Robert, Xue, Liting, Eide, Christopher A., Ou, Jianhong, Zhu, Lihua J., Hutchinson, Lloyd, Cerny, Jan, Khoury, Hanna Jean, Sheng, Zhi, Druker, Brian J., Li, Shaoguang, Green, Michael R.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4162097/
https://ncbi.nlm.nih.gov/pubmed/25186176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3009073
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares